安菲瑞古林/EGFR轴对控制自身免疫性糖尿病的贡献有限
Arielle Raugh1,2, Yi Jing3,2, Matthew L Bettini2
1Translational Biology and Molecular Medicine Program, Baylor College of Medicine, Houston, Texas, 77030, USA.
Research square
|August 14, 2023
概括
调节性T细胞 (Tregs) 产生安菲瑞古林,可能有助于1型糖尿病的组织修复. 然而,这项研究发现,安菲瑞古林缺乏在NOD小鼠中没有加速自身免疫糖尿病,这表明影响有限.
科学领域:
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
- 细胞生物学 细胞生物学
背景情况:
- 已知CD4+Foxp3+调节性T细胞 (Tregs) 在1型糖尿病 (T1D) 中具有免疫抑制作用.
- 新兴研究强调了Treg在组织修复中的作用,包括皮生长因子受体 (EGFR) 的配体安菲瑞古林的产生.
- 在胰腺小岛恒温和自身免疫性糖尿病进展中Treg衍生的安菲瑞古林的作用尚不清楚.
研究的目的:
- 调查Tregs在T1D病变发生中的非免疫功能.
- 确定Tregs产生的安菲瑞古林及其在胰腺小岛与EGFR的相互作用是否影响T1D进展.
- 评估安菲瑞古林缺乏对非肥胖糖尿病 (NOD) 小鼠自身免疫糖尿病的影响.
主要方法:
- 从NOD小鼠的岛屿透Tregs中分析安菲瑞古林表达.
- 对Tregs和β细胞的EGFR表达的评估.
- 在体内研究中,使用缺乏安菲瑞古林的NOD小鼠来评估自身免疫糖尿病的进展.
- 对安菲瑞古林对β细胞内质网膜 (ER) 压力介质的直接作用的研究.
主要成果:
- 透小岛的Tregs在NOD小鼠中表现出对安菲瑞古林生产的增强能力.
- 两种Tregs和胰腺β细胞都表达EGFR,这表明一个潜在的信号轴.
- 发现安菲瑞古林直接调节β细胞中的ER压力介质.
- 缺乏安菲瑞古林的NOD小鼠没有表现出加速自发性自身免疫糖尿病.
结论:
- 虽然Tregs在胰腺小岛环境中产生安菲瑞古林并与EGFR相互作用,但其在调节自身免疫糖尿病进展中的作用似乎有限.
- 该研究表明,在NOD模型中,Treg介导的安菲瑞古林信号可能不是自身免疫糖尿病发展或进展的关键因素.
- 可能需要进一步的研究,以充分阐明Tregs在T1D中的复杂功能,并确定其他潜在的组织保护机制.
相关概念视频
Autoimmune Disorders
494
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
494
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
2.2K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.2K
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
Insulin: The Receptor and Signaling Pathways
1.3K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.3K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Glucagon-like Receptor Agonists
358
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358


